Edesa Biotech, Inc. (EDSA) vs Grace Therapeutics, Inc. (GRCE)

A side-by-side comparison of Edesa Biotech, Inc. and Grace Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

EDSA

Edesa Biotech, Inc.

$36M

$3.76HealthcareDelayed quote: Oct 6, 2026, 3:34 PM EDT

GRCE

Grace Therapeutics, Inc.

$34M

$2.11HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT

Total return — EDSA vs GRCE

growth of $100 · dividends reinvested · last 2y

EDSA -9.9% (-5.1%/yr)GRCE -31.6% (-17.3%/yr)EDSA compounded faster over this window

EDSA GRCE

EDSA vs GRCE: by the numbers

•EDSA is the larger company ($36M vs $34M market cap).

Metrics side by side

Valuation

Metric	EDSA	GRCE
P/B ratio	90.66	0.71

Profitability

Metric	EDSA	GRCE
Gross margin	0.00%	0.00%
Operating margin	0.00%	0.00%
Net margin	0.00%	0.00%
ROE	-160.05%	-44.50%
ROIC	-166.02%	-52.61%

Growth (annualized)

Metric	EDSA	GRCE
Total return CAGR (5Y)	-39.88%	N/A

Go deeper

Full EDSA analysis Full GRCE analysis Interactive comparison tool

Dig into the metrics

Edesa Biotech ROE Grace Therapeutics ROE Edesa Biotech operating margin Grace Therapeutics operating margin Edesa Biotech revenue growth Grace Therapeutics revenue growth Edesa Biotech free cash flow Grace Therapeutics free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.